Strategy& surveyed key players and experts in the pharmaceutical industry to understand the hurdles and opportunities Pharma faces in emerging markets.
We pose dozens of questions to CEO’s regarding trends in the global economy and their impact, the business environment of certain countries, and the overall mood in the entrepreneurial world.
Pharmaceutical companies face a major challenge that threatens reimbursement and value capture: The potential disruption from real world evidence (RWE) as a factor in evaluating new drugs.
The pharmaceutical industry is at a critical juncture.
Bribery and corruption stands out as a big issue for pharmaceuticals and life sciences companies in our Global Economic Crime Survey 2014.
Innovation in pharmaceuticals has a dramatic impact both on the health and wellness of millions of people and the bottom lines of the companies in the sector.
A variety of factors can impact and frustrate consumers during their treatment experience.
The publication represents an authoritative analysis of accounting issues that the industry face.
This year we interviewed 90 Pharmaceuticals & Life Sciences CEOs in 37 countries.
The pharmaceutical industry is undergoing a commercial evolution. Traditional sales and marketing tactics — such as the classic in-person sales rep model — have declined, leading companies to invest in new commercial models (NCMs).